T1	PROC 1 41	Tratamiento de inducción y mantenimiento
#1	AnnotatorNotes T1	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure + C0857127; Induction procedure; Therapeutic or Preventive Procedure
T2	CHEM 46 56	adalimumab
#2	AnnotatorNotes T2	C1122087; adalimumab; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T3	DISO 63 82	enfermedad de Crohn
#3	AnnotatorNotes T3	C0010346; Crohn Disease; Disease or Syndrome
T4	PROC 87 102	estudio abierto
#4	AnnotatorNotes T4	C1709323; Open Label Study; Research Activity
T5	DISO 240 271	EC luminal y fistulosa perianal
T6	CHEM 121 131	adalimumab
#5	AnnotatorNotes T6	C1122087; adalimumab; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T7	PROC 150 190	ensayos clínicos controlados con placebo
#6	AnnotatorNotes T7	C0599724; placebo controlled study; Research Activity · Intellectual Product
T8	PROC 196 219	estudios no controlados
#7	AnnotatorNotes T8	C0681868; Uncontrolled Study; Research Activity
T9	CHEM 580 583	IFX
#8	AnnotatorNotes T9	C0666743; infliximab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T10	CHEM 1313 1316	IFX
#9	AnnotatorNotes T10	C0020823; ifosfamide; Organic Chemical · Pharmacologic Substance (?)
T11	ANAT 263 271	perianal
#10	AnnotatorNotes T11	C0442158; Perianal; Body Location or Region
T12	PROC 284 315	evaluar la eficacia y seguridad
#11	AnnotatorNotes T12	C0511730; Identify product efficacy and safety issues; Health Care Activity
T13	CHEM 320 330	adalimumab
#12	AnnotatorNotes T13	C1122087; adalimumab; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T14	DISO 383 385	EC
#13	AnnotatorNotes T14	C0010346; Crohn Disease; Disease or Syndrome
T15	PROC 435 443	tratados
#14	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 432 434	EC
#15	AnnotatorNotes T16	C0010346; Crohn Disease; Disease or Syndrome
T17	CHEM 448 458	adalimumab
#16	AnnotatorNotes T17	C1122087; adalimumab; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T18	DISO 467 485	enfermedad luminal
T19	CHEM 1424 1427	IFX
#17	AnnotatorNotes T19	C0020823; ifosfamide; Organic Chemical · Pharmacologic Substance (?)
T20	DISO 494 523	enfermedad fistulosa perianal
T21	ANAT 515 523	perianal
#18	AnnotatorNotes T21	C0442158; Perianal; Body Location or Region
T22	PROC 1704 1717	mantenimiento
#19	AnnotatorNotes T22	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T23	PROC 740 768	tratamiento de mantenimiento
#20	AnnotatorNotes T23	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T24	DISO 976 994	enfermedad luminal
T25	DISO 1256 1287	reacciones de hipersensibilidad
#21	AnnotatorNotes T25	C0020517; Hypersensitivity; Pathologic Function
T26	DISO 1342 1371	enfermedad fistulosa perianal
T27	ANAT 1363 1371	perianal
#22	AnnotatorNotes T27	C0442158; Perianal; Body Location or Region
T28	PROC 1408 1419	tratamiento
#23	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	PROC 1598 1609	seguimiento
#24	AnnotatorNotes T29	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T30	CHEM 1641 1651	adalimumab
#25	AnnotatorNotes T30	C1122087; adalimumab; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T31	PROC 1658 1669	tratamiento
#26	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	DISO 1740 1771	EC luminal y fistulosa perianal
T33	ANAT 1763 1771	perianal
#27	AnnotatorNotes T33	C0442158; Perianal; Body Location or Region
T34	PROC 336 376	tratamiento de inducción y mantenimiento
#28	AnnotatorNotes T34	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure + C0857127; Induction procedure; Therapeutic or Preventive Procedure
T35	PROC 596 620	tratamiento de inducción
#29	AnnotatorNotes T35	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T36	PROC 937 946	inducción
#30	AnnotatorNotes T36	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T37	PROC 1437 1446	inducción
#31	AnnotatorNotes T37	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T38	PROC 1692 1701	inducción
#32	AnnotatorNotes T38	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T39	PROC 1835 1863	ensayos clínicos controlados
#33	AnnotatorNotes T39	C0681867; Controlled Study; Research Activity
T40	PROC 1888 1904	práctica clínica
T42	LIVB 418 427	pacientes
#34	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	LIVB 542 551	pacientes
#35	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	Dose 625 631	160 mg
T45	Route 632 636	s.c.
#36	AnnotatorNotes T45	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T46	Date 640 651	la semana 0
T47	Dose 654 659	80 mg
T48	Route 660 664	s.c.
#37	AnnotatorNotes T48	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T49	Duration 667 680	las 2 semanas
T50	Dose 711 716	40 mg
T51	Route 717 721	s.c.
#38	AnnotatorNotes T51	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T52	Frequency 722 734	cada 14 días
T53	Duration 795 808	las 4 semanas
T55	LIVB 962 971	pacientes
#39	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	Duration 1087 1090	año
T57	LIVB 1110 1119	pacientes
#40	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Duration 1123 1135	los 18 meses
T59	Duration 1152 1164	los 48 meses
T61	LIVB 1230 1239	pacientes
#41	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 1328 1337	pacientes
#42	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	LIVB 1525 1534	pacientes
#43	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Duration 1613 1621	15 meses
T65	Frequency 1905 1911	diaria
A1	Status T9 History_of
T41	CONC 1196 1207	diferencias
A2	Assertion T41 Negated
#44	AnnotatorNotes T41	C1705241; Delta (difference); Quantitative Concept
T54	Neg_cue 1178 1180	No
R1	Negation Arg1:T54 Arg2:T41	
T60	Neg_cue 205 207	no
T66	Quantifier_or_Qualifier 208 219	controlados
A3	Assertion T66 Negated
R2	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T66	
R3	Negation Arg1:T60 Arg2:T66	
T67	Neg_cue 893 904	ausencia de
T68	Observation 905 914	respuesta
A4	Assertion T68 Negated
#45	AnnotatorNotes T68	C4055223; Clinical Response; Finding (?)
T69	Observation 863 871	remisión
#46	AnnotatorNotes T69	C0544452; Disease remission; Finding
T70	Observation 873 890	respuesta parcial
#47	AnnotatorNotes T70	C1521726; partial response; Finding
R4	Used_for Arg1:T2 Arg2:T1	
R6	Location_of Arg1:T11 Arg2:T5	
R7	Used_for Arg1:T13 Arg2:T34	
R8	Experiences Arg1:T42 Arg2:T16	
R9	Used_for Arg1:T17 Arg2:T15	
R10	Experiences Arg1:T42 Arg2:T15	
R11	Experiences Arg1:T42 Arg2:T18	
R12	Location_of Arg1:T21 Arg2:T20	
R13	Experiences Arg1:T42 Arg2:T20	
T72	Quantifier_or_Qualifier 524 530	activa
#49	AnnotatorNotes T72	C0679217; Active State; Idea or Concept
R14	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T72	
R15	Experiences Arg1:T43 Arg2:T9	
R16	Has_Dose_or_Strength Arg1:T35 Arg2:T44	
R17	Has_Route_or_Mode Arg1:T35 Arg2:T45	
R18	Overlap Arg1:T35 Arg2:T46	
R19	Has_Dose_or_Strength Arg1:T35 Arg2:T47	
R20	Has_Route_or_Mode Arg1:T35 Arg2:T48	
R21	Has_Duration_or_Interval Arg1:T35 Arg2:T49	
T73	Observation 686 699	respondedores
#50	AnnotatorNotes T73	C0919876; Therapy responder; Finding
R22	Has_Frequency Arg1:T23 Arg2:T52	
R23	Has_Route_or_Mode Arg1:T23 Arg2:T51	
R24	Has_Dose_or_Strength Arg1:T23 Arg2:T50	
R25	Before Arg1:T73 Arg2:T23	
T74	Observation 783 792	respuesta
#51	AnnotatorNotes T74	C4055223; Clinical Response; Finding (?)
R26	Overlap Arg1:T74 Arg2:T53	
R27	Negation Arg1:T67 Arg2:T68	
R28	Overlap Arg1:T69 Arg2:T53	
R29	Overlap Arg1:T70 Arg2:T53	
R30	Overlap Arg1:T68 Arg2:T53	
T75	Quantifier_or_Qualifier 821 828	inicial
#52	AnnotatorNotes T75	C0205265; Initially; Temporal Concept 
T76	CONC 815 820	dosis
#53	AnnotatorNotes T76	C0178602; Dosage; Quantitative Concept
R31	Has_Quantifier_or_Qualifier Arg1:T76 Arg2:T75	
R32	Before Arg1:T76 Arg2:T74	
R34	Experiences Arg1:T55 Arg2:T36	
R35	Experiences Arg1:T55 Arg2:T24	
T77	Observation 1004 1021	remisión completa
#54	AnnotatorNotes T77	C0544452; Disease remission; Finding
R37	Before Arg1:T36 Arg2:T77	
R36	Experiences Arg1:T55 Arg2:T77	
T78	Observation 1033 1050	respuesta parcial
#55	AnnotatorNotes T78	C1521726; partial response; Finding
R38	Experiences Arg1:T55 Arg2:T78	
R39	Before Arg1:T36 Arg2:T78	
T79	Observation 1055 1072	respuesta clínica
#56	AnnotatorNotes T79	C4055223; Clinical Response; Finding (?)
R40	Has_Duration_or_Interval Arg1:T79 Arg2:T56	
R41	Experiences Arg1:T57 Arg2:T79	
R42	Has_Duration_or_Interval Arg1:T79 Arg2:T58	
R43	Has_Duration_or_Interval Arg1:T79 Arg2:T59	
T80	Observation 1214 1223	respuesta
#57	AnnotatorNotes T80	C4055223; Clinical Response; Finding (?)
R44	Experiences Arg1:T61 Arg2:T80	
R45	Experiences Arg1:T61 Arg2:T25	
R46	Causes Arg1:T10 Arg2:T25	
T81	Observation 1290 1310	pérdida de respuesta
#58	AnnotatorNotes T81	C5400193; Loss of therapeutic response; Finding 
R47	Experiences Arg1:T61 Arg2:T81	
R48	Experiences Arg1:T61 Arg2:T10	
R49	Overlap Arg1:T81 Arg2:T10	
R50	Location_of Arg1:T27 Arg2:T26	
R51	Experiences Arg1:T62 Arg2:T26	
R52	Used_for Arg1:T19 Arg2:T28	
R53	Experiences Arg1:T62 Arg2:T28	
A5	Status T28 History_of
A6	Status T19 History_of
T82	Observation 1496 1513	respuesta parcial
#59	AnnotatorNotes T82	C1521726; partial response; Finding
R54	Before Arg1:T37 Arg2:T82	
T83	Observation 1466 1474	remisión
#60	AnnotatorNotes T83	C0544452; Disease remission; Finding
R55	Before Arg1:T37 Arg2:T83	
T84	Observation 1545 1553	remisión
#61	AnnotatorNotes T84	C0544452; Disease remission; Finding
R56	Experiences Arg1:T63 Arg2:T84	
T85	Observation 1556 1565	respuesta
#62	AnnotatorNotes T85	C4055223; Clinical Response; Finding (?)
R57	Experiences Arg1:T63 Arg2:T85	
R58	Has_Duration_or_Interval Arg1:T29 Arg2:T64	
R61	Used_for Arg1:T30 Arg2:T31	
T86	Observation 1724 1733	respuesta
#63	AnnotatorNotes T86	C4055223; Clinical Response; Finding (?)
R64	Location_of Arg1:T33 Arg2:T32	
R65	Overlap Arg1:T30 Arg2:T86	
R68	Overlap Arg1:T40 Arg2:T65	
T88	Observation 848 857	respuesta
#65	AnnotatorNotes T88	C4055223; Clinical Response; Finding (?)
R71	Overlap Arg1:T88 Arg2:T53	
R33	Before Arg1:T24 Arg2:T77	
R72	Before Arg1:T24 Arg2:T78	
#48	AnnotatorNotes T20	C4518828; Perianal fistula due to Crohn's disease; Disease or Syndrome (?)
#64	AnnotatorNotes T26	C4518828; Perianal fistula due to Crohn's disease; Disease or Syndrome (?)
A7	Experiencer T63 Patient
A8	Experiencer T62 Patient
A9	Experiencer T61 Patient
A10	Experiencer T57 Patient
A11	Experiencer T55 Patient
A12	Experiencer T43 Patient
A13	Experiencer T42 Patient
